コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 e radiation sickness and patients undergoing hematopoietic cell transplantation.
2 relevant to local wound therapy and systemic hematopoietic cell transplantation.
3 of morbidity and mortality after allogeneic hematopoietic cell transplantation.
4 of morbidity and mortality after allogeneic hematopoietic cell transplantation.
5 d leukemia in children undergoing allogeneic hematopoietic cell transplantation.
6 No patients were cured without hematopoietic cell transplantation.
7 radicate tumor and to enhance outcomes after hematopoietic cell transplantation.
8 of damaged host tissues following allogeneic hematopoietic cell transplantation.
9 ut still had fatal complications or required hematopoietic cell transplantation.
10 t rejection or chronic GVHD after allogeneic hematopoietic cell transplantation.
11 d be considered as candidates for allogeneic hematopoietic cell transplantation.
12 D) can result in disability after allogeneic hematopoietic cell transplantation.
13 e peripheral blood stem cells for allogeneic hematopoietic cell transplantation.
14 he tumor site in cooperation with allogeneic hematopoietic cell transplantation.
15 afety and efficacy of alternative donors for hematopoietic cell transplantation.
16 ogic diseases who can be cured by allogeneic hematopoietic cell transplantation.
17 mediate a novel immunoregulatory role during hematopoietic cell transplantation.
18 epresenting a primary NK cell response after hematopoietic cell transplantation.
19 undamental obstacle to successful allogeneic hematopoietic cell transplantation.
20 rly intervention and improved survival after hematopoietic cell transplantation.
21 atment of hematologic malignancies and after hematopoietic cell transplantation.
22 and their potential applications in clinical hematopoietic cell transplantation.
23 of patients can proceed to alternative donor hematopoietic cell transplantation.
24 o CMV reactivation in human recipients after hematopoietic cell transplantation.
25 a major source of morbidity after allogeneic hematopoietic cell transplantation.
26 y, for consideration of potentially curative hematopoietic cell transplantation.
27 ablation is commonly used in solid organ and hematopoietic cell transplantation.
28 -versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation.
29 ficant obstacle to the success of allogeneic hematopoietic cell transplantation.
30 m of graft-versus-host interaction following hematopoietic cell transplantation.
31 ietic stem cells (HSCs) during an allogeneic hematopoietic cell transplantation.
32 myeloid leukemia (AML) following allogeneic hematopoietic cell transplantation.
33 Interventions: Unrelated donor BM or PB hematopoietic cell transplantation.
34 in human and murine T cells after allogeneic hematopoietic cell transplantation.
35 uction syndrome, an early complication after hematopoietic cell transplantation.
36 major nonrelapse complication of allogeneic hematopoietic cell transplantation.
37 blood from unrelated donors may be used for hematopoietic cell transplantation.
38 life-threatening complication of allogeneic hematopoietic cell transplantation.
39 re white; 45% had leukemia; and 34% received hematopoietic cell transplantation.
40 fection before starting anti-CD20 therapy or hematopoietic cell transplantation.
41 th in patients who have undergone allogeneic hematopoietic-cell transplantation.
42 001 in patients who had undergone allogeneic hematopoietic-cell transplantation.
43 VHD) is the major complication of allogeneic hematopoietic cell transplantation, a potentially curati
44 es influence clinical outcomes in autologous hematopoietic cell transplantation (AHCT) for acute myel
45 ) cells mediate GVL effects after allogeneic hematopoietic cell transplantation (allo-HCT) by the pro
46 GVHD) is a severe complication of allogeneic hematopoietic cell transplantation (allo-HCT) characteri
49 immune reconstitution (IR) after allogeneic hematopoietic cell transplantation (allo-HCT) is highly
52 treatment of acute leukemias with allogeneic hematopoietic cell transplantation (allo-HCT) is limited
53 t-versus-tumor (GVT) effect after allogeneic hematopoietic cell transplantation (allo-HCT) represents
54 vHD) is a serious complication of allogeneic hematopoietic cell transplantation (allo-HCT) that resul
55 tic potential of Fn14 blockade on allogeneic hematopoietic cell transplantation (allo-HCT)-induced in
61 ease (GVHD) limits the success of allogeneic hematopoietic cell transplantation (allo-HCT); therefore
62 e major causes of mortality after allogeneic hematopoietic-cell transplantation (allo-HCT) are relaps
63 solution for patients who require allogeneic hematopoietic cell transplantation (alloHCT) but lack a
67 LSFM to map individual T cell subsets after hematopoietic cell transplantation and detected rare cel
68 eady-state and stressful conditions, such as hematopoietic cell transplantation and G-CSF- or inflamm
69 n adoptively transferred in murine models of hematopoietic cell transplantation and in phase 1/2 clin
70 ncies, assessing immune reconstitution after hematopoietic cell transplantation, and characterizing t
71 VHD) is the primary limitation of allogeneic hematopoietic cell transplantation, and once it develops
72 be used as a novel conditioning regimen for hematopoietic cell transplantation, and raise concerns f
75 istocompatibility complex-matched allogeneic hematopoietic cell transplantation as a platform to deve
76 in the hazard of death related to allogeneic hematopoietic-cell transplantation, as well as increased
77 This information may be useful for enhancing hematopoietic cell transplantation, blood cell recovery
78 imen that prepares recipients for allogeneic hematopoietic cell transplantation by targeting lymph no
79 formation in a model that simulates clinical hematopoietic cell transplantation by transplanting MHC-
83 e phenotype of chronic GVHD after allogeneic hematopoietic cell transplantation, characterized by fib
86 the other hand, older recipient age and high hematopoietic cell transplantation-comorbidity index (HC
88 ncluding those already incorporated into the hematopoietic cell transplantation-comorbidity index (HC
89 linical trial using low-intensity allogeneic hematopoietic cell transplantation demonstrated that int
91 depletion of donor CD4+ T cells early after hematopoietic cell transplantation effectively prevents
92 an adaptive immune system through allogeneic hematopoietic cell transplantation, enzyme replacement,
93 ection to improve outcome of unrelated donor hematopoietic cell transplantation for acute myelogenous
94 analyzed trends in outcomes after autologous hematopoietic cell transplantation for AL in North Ameri
95 w (BM) vs peripheral blood (PB) (N = 551) in hematopoietic cell transplantation for hematologic neopl
96 ic lymphohistiocytosis (HLH), which requires hematopoietic cell transplantation for long-term cure.
100 s of the consortium describe the outcomes of hematopoietic cell transplantation for SCID during 2000-
101 n solid organ transplantation patients given hematopoietic cell transplantation from human leukocyte
103 ituted NK cells obtained from patients after hematopoietic cell transplantation had diminished expres
108 antibodies and cellular immunotherapy using hematopoietic cell transplantation have recently culmina
110 and 100 cGy total body irradiation prior to hematopoietic cell transplantation (HCT) and a 45-day co
111 udy examined the quality of life (QOL) after hematopoietic cell transplantation (HCT) and identified
113 of approximately 40% of patients undergoing hematopoietic cell transplantation (HCT) and sporadicall
114 tranded DNA (dsDNA) viruses after allogeneic hematopoietic cell transplantation (HCT) are limited by
115 ighlights long-term and late consequences of hematopoietic cell transplantation (HCT) as well as stra
117 ge (median, 51.5 years of age), who received hematopoietic cell transplantation (HCT) between 1990 an
118 ome (MDS) (n = 371) who underwent allogeneic hematopoietic cell transplantation (HCT) between 1995 an
122 a 23% improvement in day +100 survival after hematopoietic cell transplantation (HCT) compared with h
123 ary complications (LONIPCs) after allogeneic hematopoietic cell transplantation (HCT) contribute to p
125 mal residual disease (MRD) before allogeneic hematopoietic cell transplantation (HCT) correlates with
126 ta from genome-wide scans of 1298 allogeneic hematopoietic cell transplantation (HCT) donors and reci
127 y cause of poor outcome following allogeneic hematopoietic cell transplantation (HCT) for chronic lym
129 of hypomethylating agents in the setting of hematopoietic cell transplantation (HCT) for myelodyspla
130 es are a major risk factor for relapse after hematopoietic cell transplantation (HCT) for myelodyspla
131 In this review we discuss recent outcomes of hematopoietic cell transplantation (HCT) for patients wi
132 cells after allogeneic-matched sibling donor hematopoietic cell transplantation (HCT) for therapy of
133 We analyzed patients treated with allogeneic hematopoietic cell transplantation (HCT) from 2010 to 20
135 Induction of mixed or complete chimerism via hematopoietic cell transplantation (HCT) from nonautoimm
137 st disease (GVHD) is higher after allogeneic hematopoietic cell transplantation (HCT) from unrelated
140 g neurodegenerative disease; only allogeneic hematopoietic cell transplantation (HCT) has been shown
143 one-third of patients with an indication for hematopoietic cell transplantation (HCT) have an HLA-mat
144 GVHD) in several animal models and following hematopoietic cell transplantation (HCT) in clinical tri
145 ntensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients wit
146 studies on patient outcome after allogeneic hematopoietic cell transplantation (HCT) in patients wit
147 intensity treatments and complications after hematopoietic cell transplantation (HCT) injure normal t
150 ysosomal storage disorders (LSDs), for which hematopoietic cell transplantation (HCT) is applied to r
151 residual disease (MRD) before myeloablative hematopoietic cell transplantation (HCT) is associated w
153 no acid (AA) polymorphism for the outcome of hematopoietic cell transplantation (HCT) is controversia
159 ntial component of allogeneic and autologous hematopoietic cell transplantation (HCT) is the conditio
163 optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is unknown.
164 geneic (allo-allo) or autologous (auto-allo) hematopoietic cell transplantation (HCT) is usually perf
165 y multichannel flow cytometry (MFC) prior to hematopoietic cell transplantation (HCT) of patients wit
167 VHD) remains a major challenge in allogeneic hematopoietic cell transplantation (HCT) owing to limite
168 may substitute for total-body irradiation in hematopoietic cell transplantation (HCT) preparative reg
169 prophylaxis after matched-related allogeneic hematopoietic cell transplantation (HCT) recently showed
171 % of matched, related donor (MRD) allogeneic hematopoietic cell transplantation (HCT) recipients.
172 ) infection is a significant complication in hematopoietic cell transplantation (HCT) recipients.
176 e the risks of serious health outcomes among hematopoietic cell transplantation (HCT) survivors versu
179 et al. tackle one of the major obstacles in hematopoietic cell transplantation (HCT) technology: bal
180 trajectory of sexual well-being from before hematopoietic cell transplantation (HCT) to 3 years afte
181 rrent outcomes of unrelated donor allogeneic hematopoietic cell transplantation (HCT) to determine th
182 blative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patien
183 nderwent myeloablative HLA-matched unrelated hematopoietic cell transplantation (HCT) were randomly a
185 uced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) with alemtuzuma
186 matched sibling donors (MSDs) can proceed to hematopoietic cell transplantation (HCT) without conditi
187 mportant to understand the economic costs of hematopoietic cell transplantation (HCT), a procedure th
188 s received total body irradiation (4.5 cGy), hematopoietic cell transplantation (HCT), either marrow
189 etic stem cell (HSC) homing is important for hematopoietic cell transplantation (HCT), especially whe
190 us (PIV) commonly infects patients following hematopoietic cell transplantation (HCT), frequently cau
191 ed donor-host chimerism, established through hematopoietic cell transplantation (HCT), is a reproduci
192 ce and in patients undergoing HLA-mismatched hematopoietic cell transplantation (HCT), NK cells deriv
195 nio rerio, is an emerging model for studying hematopoietic cell transplantation (HCT), the role of SD
196 ith hematologic malignancies cannot tolerate hematopoietic cell transplantation (HCT), whereas others
197 logy) in treatment algorithms for allogeneic hematopoietic cell transplantation (HCT), which implies
199 r high-dose treatment followed by allogeneic hematopoietic cell transplantation (HCT), with partial r
243 inib use, but its cytomegalovirus risk after hematopoietic-cell transplantation (HCT) is not known.
244 ning disease of infants that is curable with hematopoietic cell transplantation if detected early.
246 high-risk leukemia, who underwent allogeneic hematopoietic cell transplantation in 2 sequential treat
249 al donors, and the role of alternative donor hematopoietic cell transplantation in thalassemia is not
251 verse outcomes after matched unrelated donor hematopoietic cell transplantations in US patients.
252 sortium was formed to analyze the results of hematopoietic-cell transplantation in children with seve
254 ajor barrier to successful use of allogeneic hematopoietic cell transplantation is acute graft-versus
261 sion acute myeloid leukemia patients receive hematopoietic cell transplantation is referred to as ris
262 ell reconstitution following T cell-depleted hematopoietic cell transplantation is slow, resulting in
263 t of choice for neutropenia in PIDD, whereas hematopoietic cell transplantation is the only curative
264 e moving target of which patients to take to hematopoietic cell transplantation is to define those wi
266 Evidence supporting the efficacy of in utero hematopoietic cell transplantation (IUHCT) in a valid la
269 stational fetus, a treatment termed in utero hematopoietic cell transplantation (IUHCTx), could poten
270 sociated with HLA-mismatched unrelated donor hematopoietic cell transplantation limit its general app
271 therapy given in preparation for allogeneic hematopoietic cell transplantation may prime donor T cel
272 ency, early and late complications following hematopoietic cell transplantation might be more promine
274 cute myeloid leukemia patients proceeding to hematopoietic cell transplantation, now the most common
275 supporting the use of alternative donors for hematopoietic cell transplantation of patients with high
277 nt opportunistic pathogen in solid organ and hematopoietic cell transplantation, particularly in lung
279 utcome of 2687 myeloablative unrelated donor hematopoietic cell transplantations performed for malign
280 ptions for relapsed lymphoma post-allogeneic hematopoietic cell transplantation (post-allo-HCT) and t
283 ting equations (that adjusted for diagnosis, hematopoietic cell transplantation, race/ethnicity, and
284 ctively, and those from 140 URI samples from hematopoietic cell transplantation recipients were 88% a
285 parate EBV-specific T cells (EBV-CTLs) in 49 hematopoietic cell transplantation recipients with biops
286 ntaining at least 100 patients who underwent hematopoietic cell transplantation reporting skin cancer
288 when hosts are sublethally irradiated before hematopoietic cell transplantation, stable and long-term
290 daptive immune response caused by allogeneic hematopoietic cell transplantation that have been activa
291 cGVHD) is a major complication of allogeneic hematopoietic cell transplantation that is associated wi
292 clearly influences the outcome of unrelated hematopoietic cell transplantation; the magnitude of thi
293 a primary hindrance to successful allogeneic hematopoietic cell transplantation therapy for the treat
294 ansplantation regimen followed by autologous hematopoietic cell transplantation versus rituximab with
295 To investigate the role of mast cells in hematopoietic cell transplantation, we assessed graft-ve
296 In this study, recipients of adult donor hematopoietic cell transplantation were assessed to eval
297 LC-chimerism after sex-mismatched allogeneic hematopoietic cell transplantation with nonmyeloablative
298 mide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of p
299 f treatment, compared with 27 patients after hematopoietic cell transplantation without aGVHD (NONE).
300 uld prevent and treat leukemic relapse after hematopoietic cell transplantation without causing graft
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。